What adjuvant chemoradiotherapy regimen was studied in the PORTEC‑3 trial for high‑risk endometrial cancer, and what were the efficacy and toxicity outcomes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PORTEC-3 Trial: Adjuvant Chemoradiotherapy for High-Risk Endometrial Cancer

The PORTEC-3 trial studied combined chemoradiotherapy (cisplatin 50 mg/m² on days 1 and 29 during pelvic external beam radiotherapy [48.6 Gy], followed by 4 cycles of carboplatin AUC 5 plus paclitaxel 175 mg/m² every 3 weeks) versus radiotherapy alone in 686 patients with high-risk endometrial cancer, demonstrating improved 5-year overall survival (81.4% vs 76.1%, HR 0.70, p=0.034) and failure-free survival (76.5% vs 69.1%, HR 0.70, p=0.016), with the greatest benefit seen in stage III disease and serous histology. 1, 2, 3

Trial Design and Patient Population

The PORTEC-3 trial enrolled women with high-risk endometrial cancer defined as:

  • Stage I, grade 3 with deep myometrial invasion AND lymphovascular space invasion (LVSI)
  • Stage II (any grade)
  • Stage III (any grade, endometrioid histology)
  • Stage I-III serous or clear cell carcinoma 1, 2

This represented approximately 15% of all endometrial cancer patients, with about half having high-risk early-stage disease and 45% having stage III disease 4, 5.

Treatment Regimen Details

Chemoradiotherapy Arm:

  • Concurrent phase: Cisplatin 50 mg/m² IV on day 1 and day 29 during pelvic EBRT (48.6 Gy in 1.8 Gy fractions, 5 days/week)
  • Adjuvant phase: Carboplatin AUC 5 + paclitaxel 175 mg/m² IV every 3 weeks × 4 cycles (escalated to AUC 6 in subsequent cycles as tolerated) 1, 4, 2

Radiotherapy Alone Arm:

  • Pelvic EBRT 48.6 Gy in 1.8 Gy fractions, 5 days/week 1, 2

Efficacy Outcomes

At median follow-up of 72.6 months 3:

Overall Survival:

  • 5-year OS: 81.4% (chemoradiotherapy) vs 76.1% (radiotherapy alone)
  • Hazard ratio: 0.70 (95% CI 0.51-0.97, p=0.034) 1, 3

Failure-Free Survival:

  • 5-year FFS: 76.5% (chemoradiotherapy) vs 69.1% (radiotherapy alone)
  • Hazard ratio: 0.70 (95% CI 0.52-0.94, p=0.016) 1, 3

Recurrence Patterns:

Distant metastases were the predominant site of first recurrence, occurring in 21.4% with chemoradiotherapy versus 29.1% with radiotherapy alone (HR 0.74, p=0.047). Isolated vaginal recurrence was rare (0.3% in both groups), and isolated pelvic recurrence occurred in only 0.9% of patients in each arm 3.

Subgroup Analysis: Who Benefits Most?

Patients with stage III disease and serous histology derived the greatest benefit from combined therapy 1. For stage I-II non-serous cancers, the absolute improvement was modest (2% in 5-year OS, 4% in FFS), making the decision for combined treatment more nuanced in this subgroup 6.

Molecular Subtype Analysis:

A critical follow-up molecular analysis stratified outcomes by molecular classification 1:

  • p53 abnormal: 5-year RFS 59% (chemoradiotherapy) vs 36% (radiotherapy) - substantial benefit
  • POLE mutated: 100% vs 97% - excellent outcomes regardless
  • MMR-deficient: 68% vs 76% - no benefit, possibly worse with chemotherapy
  • No specific molecular profile: 80% vs 68% - moderate benefit

This molecular data suggests systemic therapy is most beneficial for p53 abnormal tumors and should be considered carefully in MMR-deficient disease 1.

Toxicity Profile

Acute Toxicity (During Treatment):

  • Grade ≥3 adverse events: 60% (chemoradiotherapy) vs 12% (radiotherapy alone), p<0.0001
  • Most grade 3 events were hematological toxicity (45%) 5
  • Grade ≥2 adverse events: 94% vs 44% 5

Long-Term Toxicity (5 Years):

  • Grade ≥2 adverse events: 38% (chemoradiotherapy) vs 24% (radiotherapy alone), p=0.008 7
  • Grade 3 adverse events: 8% vs 5%, p=0.18 (not significantly different) 7, 3
  • Only one new late grade 4 toxicity (ileus/obstruction) reported at 5 years 3

Persistent Sensory Neuropathy - The Major Long-Term Issue:

Sensory neuropathy represents the most clinically significant persistent toxicity:

  • At 3 years: Grade ≥2 neuropathy in 8% (chemoradiotherapy) vs 0% (radiotherapy alone), p<0.001 7
  • At 5 years: Grade ≥2 neuropathy in 6% vs 0%, p<0.001 7, 3
  • Patient-reported tingling/numbness at 3 years: 27% vs 8%, p<0.001 7
  • Patient-reported tingling/numbness at 5 years: 24% vs 9%, p=0.002 7

This persistent neuropathy at 5 years in approximately 1 in 4 patients is a critical consideration for shared decision-making 7.

Quality of Life Impact

Early Impact (Up to 3 Years):

  • Physical functioning: Lower scores (79 vs 87, p<0.001) 7
  • Role functioning: Lower scores (78 vs 88, p<0.001) 7
  • Limb weakness: More common (21% vs 5%, p<0.001) 7

Long-Term (3-5 Years):

  • Global health/quality of life scores: Similar between groups and better than normative population 7
  • Physical and role functioning impairments resolved by 3 years, except for persistent neuropathy symptoms 7, 5

Clinical Context and Competing Evidence

GOG-258 Trial Comparison:

The GOG-258 trial compared chemoradiotherapy (similar regimen) versus chemotherapy alone (carboplatin/paclitaxel × 6 cycles) in stage III-IVA disease and found no difference in recurrence-free survival (59% vs 58%) 1, 4. This creates clinical equipoise about whether radiation adds benefit when chemotherapy is given, though OS data from GOG-258 remain pending 1.

GOG-249 Trial:

In high-intermediate risk disease, GOG-249 showed that vaginal brachytherapy plus chemotherapy was not superior to pelvic radiotherapy alone, with similar 5-year RFS and OS but significantly more acute toxicity (grade ≥2 in 94% vs 44%) and persistent neuropathy (10% vs <1% at 24 months) 6.

Treatment Compliance and Feasibility

The PORTEC-3 regimen demonstrated good feasibility:

  • No treatment discontinuation during chemoradiotherapy 8
  • 92.7% of patients completed all 4 planned adjuvant chemotherapy cycles 8
  • Similar compliance rates observed in South Asian cohorts 8

Practical Clinical Algorithm

For high-risk endometrial cancer after complete surgical staging:

  1. Stage III disease or serous/clear cell histology: Strongly recommend combined chemoradiotherapy (PORTEC-3 regimen) - absolute benefit ~5% in OS 1, 6, 3

  2. Stage I-II with p53 abnormal molecular profile: Recommend combined chemoradiotherapy - substantial benefit demonstrated in molecular subanalysis 1

  3. Stage I-II with MMR-deficient profile: Consider chemotherapy alone or clinical trial with immunotherapy; avoid routine combined therapy given lack of benefit 1

  4. Stage I-II with POLE mutation: Consider observation or de-escalated therapy given excellent prognosis 1

  5. Stage I-II with no specific molecular profile: Individualized discussion weighing modest benefit (2-4% absolute improvement) against toxicity, particularly persistent neuropathy risk 6

Critical Counseling Points

When discussing PORTEC-3 regimen with patients, emphasize:

  • Survival benefit is modest overall (5% absolute improvement in 5-year OS) but more substantial in stage III/serous histology
  • 1 in 4 patients will experience persistent tingling/numbness at 5 years that impacts quality of life 7
  • Most recurrences occur at distant sites within first 2 years (80% within 2 years), suggesting systemic therapy targets the primary failure pattern 8
  • Physical and role functioning recover by 3 years except for neuropathy 7
  • Molecular classification significantly impacts benefit - p53 abnormal tumors benefit most 1

Current Guideline Recommendations

NCCN 2023 guidelines recommend combined chemoradiotherapy for high-risk endometrial cancer based on PORTEC-3, with particular emphasis on stage III disease and serous histology 1. The ESMO 2022 guidelines similarly recommend combined therapy for high-risk disease (stage III-IVA without residual disease, or stage I-IVA p53 abnormal/non-endometrioid with myometrial invasion) 6.

The 2025 ESGO-ESTRO-ESP guidelines incorporate molecular classification, recommending external beam radiotherapy with concurrent and adjuvant chemotherapy for stage III-IVA MMR-deficient, NSMP, or p53 abnormal endometrial carcinomas, with consideration of immunotherapy for MMR-deficient disease 9.

References

Guideline

uterine neoplasms, version 1.2023, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2023

Guideline

current recommendations and recent progress in endometrial cancer.

Ca-A Cancer Journal for Clinicians, 2019

Related Questions

Did the PORTEC-3 trial provide treatment-changing guidelines for high-risk early-stage endometrial cancer in postmenopausal women?
What is the recommended protocol to rule out endometrial (uterine) cancer in a postmenopausal woman presenting with dark, mucousy vaginal spotting?
In a perimenopausal woman in her early 50s who has hot flashes, brain fog, and joint pain, and whose mother was diagnosed with endometrial, breast, and thyroid cancers in her early 60s, is hormone replacement therapy appropriate and, if so, what regimen should be used?
What do the PORTEC (Post‑Operative Radiation Therapy in Endometrial Carcinoma) trials recommend for adjuvant treatment of endometrial cancer based on risk categories?
What are examples of aggressive endometrial cancers that are limited to a polyp or confined to the endometrium?
What is the recommended treatment for Toxoplasma gondii infection?
Can alternative medicine treatments cause drug‑induced lupus nephritis?
In a patient with poorly controlled diabetes (HbA1c >7%/53 mmol/mol) and elevated triglycerides (≈6–12 mmol/L), how do these factors influence the risk of acute pancreatitis and what triglyceride thresholds in mmol/L are associated with markedly increased risk?
What are the differential diagnoses for a 1.5‑month history of progressive ascending weakness that began in the lower limbs and spread to the upper limbs, with mild sensory loss, absent plantar responses, normal spinal and brain MRI, and a recent diagnosis of pulmonary tuberculosis?
In a patient who tests positive for both nucleosome antibodies and histone antibodies, which result should be given more weight in clinical decision-making?
What is the appropriate electrolyte replacement for a patient with hypokalemia and hypophosphatemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.